

## DAFTAR PUSTAKA

1. Martinson HA, Lyons TR, Giles ED, Borges VF, Schedin P. Developmental windows of breast cancer risk provide opportunities for targeted chemoprevention. *Exp Cell Res*. 2013 Jul 1;319(11):1671-8.
2. Ng CH, Pathy NB, Taib NA, Teh YC, Mun KS, Amiruddin A, et al. Comparison of breast cancer in Indonesia and Malaysia a clinico-pathological study between Dharmais Cancer Centre Jakarta and University Malaya Medical Centre, Kuala Lumpur. *Asian Pac J Cancer Prev*. 2011;12(11):2943-6.
3. SEER-Surveillance, Epidemiology, and End Results Program [Internet]. National Cancer Institute. Table 4.5 Cancer of the Breast Invasive. Age-adjusted SEER Incidence Rates by Year, Race, and Sex[cited 2015 Mar 25]. Available from: [http://seer.cancer.gov/csr/1975\\_2012/results\\_merged/sect\\_04\\_breast.pdf](http://seer.cancer.gov/csr/1975_2012/results_merged/sect_04_breast.pdf)
4. Kim Y, Yoo KY, Goodman MT. Differences in incidence, mortality and survival of breast cancer by regions and countries in Asia and contributing factors. *Asian Pac J Cancer Prev*. 2015;16(7):2857-70.
5. Schnitt SJ. Classification and prognosis of invasive breast cancer: from morphology to molecular taxonomy. *Mod Pathol*. 2010 May;23 Suppl 2:S60-4.
6. Fleeman N, Bagust A, Boland A, Dickson R, Dundar R, Moonan M, et al. Lapatinib and trastuzumab in combination with an aromatase inhibitor for the first-line treatment of metastatic hormone receptor-positive breast cancer which over-expresses human epidermal growth factor 2 (HER2): a systematic review and economic analysis. *Health Technol Assess* 2011;15(42):1-93.
7. Eroschenko VP. Atlas histology diFiore: dengan korelasi fungsional. 11<sup>th</sup> ed. Sistem reproduksi wanita. Jakarta: EGC; 2010. p. 453-504.

8. Moore KL, Dalley AF, Agur AMR. Clinically oriented anatomy. 7<sup>th</sup> ed. Thorax. Philadelphia: Lippincott Williams & Wilkins; 2014. p. 98-106.
9. Mescher AL. Junquiera's Basic Histology text and atlas. 13<sup>th</sup> ed. The female reproductive system. New York: Mc Graw-Hill; 2013. p. 472-76.
10. Ross MH, Pawlina W. Histology A TEXT AND ATLAS-With Correlated Cell and Molecular Biology. 7<sup>th</sup> ed. Female Reproductive System. p. 866-72.
11. Tanos T, Rojo LJ, Echeverria P, Brisken C. ER and PR signaling nodes during mammary gland development. *Breast Cancer Res.* 2012 Jul 19;14(4):210-23.
12. Rao C, Shetty J, Kishan Prasad HL. Morphological profile and receptor status in breast carcinoma: an institutional study. *J Cancer Res Ther.* 2013 Jan-Mar;9(1):44-9.
13. Khabaz MN. Immunohistochemistry subtypes (ER/PR/HER) of breast cancer: where do we stand in the West of Saudi Arabia?. *Asian Pac J Cancer Prev.* 2014;15(19):8395-400.
14. Sinn HP, Kreipe H. A Brief Overview of the WHO Classification of Breast Tumors, 4th Edition, Focusing on Issues and Updates from the 3rd Edition. *Breast Care (Basel).* 2013 May; 8(2): 149–54.
15. Kumar V, Abbas AK, Fausto N, Aster JC. Robbins and Cotran Pathologic Basis of Disease. 8<sup>th</sup> ed. In: Lester SC, editors. *The Breast.* Philadelphia: Saunder Elsevier; 2010. p. 1261-97.
16. Yerushalmi R, Hayes MM, Gelmon KA. Breast carcinoma—rare types: review of the literature. *Annals of Oncology.* 2009;20:1763–70.
17. Kliegman RM, Stanton BF, Schor NF, et al. Nelson Textbook of Pediatrics. 19th ed. In: DeSilva NK, Merritt DF, editors. *Breast concern.* Philadelphia: Elsevier Saunders; 2011. p.1872-6.
18. Suba Z. Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications. *OncoTargets and Therapy.* 2014;7:147-64.

19. Kumar V, Abbas AK, Aster JC, editors. Robbins Basic. 9th ed. In: Epstein J, editor. Pathology Female genital system and breast. Philadelphia: Elsevier Saunders; 2013. p. 703-14.
20. Xu J, Chen Y, Olopade OI. MYC and Breast Cancer. *Genes Cancer*. 2010 Jun;1(6):629–640.
21. Sawyers CL. Overview Article The cancer biomarker problem. *Nature*. 2008 April 3;452:548-552.
22. Frank A, Andrew J. Obesity and Breast Cancer Prognosis: Weight of the Evidence. *JCO*. 2011 January 1;29(1):4-7.
23. Suba Z. Circulatory estrogen level protects against breast cancer in obese women. *Recent Pat Anticancer Drug Discov*. 2013 May;8(2):154-67.
24. Teegarden D, Romieu I, Lelièvre SA. Redefining the impact of nutrition on breast cancer incidence: is epigenetics involved?. *Nutr Res Rev*. 2012 Jun;25(1):68-95.
25. Rudel RA, Ackerman JM, Attfield KR, Brody JG. New Exposure Biomarkers as Tools for Breast Cancer Epidemiology, Biomonitoring, and Prevention: A Systematic Approach Based on Animal Evidence. *Environ Health Perspect*. 2014 Sep; 122(9): 881–95.
26. Rizvi F, Rajput M, Afzal M. Knowledge and Practice of Breast Self-Examination. *Journal of Rawalpindi Medical College (JRMC)*; 2013;17(1):88-90.
27. Direktorat pengendalian penyakit tidak menular-Depkes RI. Buku Saku Kanke Leher Rahim dan Kanker Payudara. Jakarta; Depkes RI: 2009. 15-8.
28. Drukteinis JS, Mooney BP, Flowers CI, Gatenby RA. Beyond mammography: new frontiers in breast cancer screening. *Am J Med*. 2013 Jun;126(6):472-9.
29. Lee CH, Dershaw DD, Kopans D, Evans P, Monsees B, Monticciolo D, et al. Breast cancer screening with imaging: recommendations from the Society of Breast Imaging and the ACR on the use of mammography, breast MRI, breast ultrasound, and other technologies for the detection of clinically occult breast cancer. *J Am Coll Radiol*. 2010 Jan;7(1):18-27.

30. Kasper DL, Fauci AS, Longo DL, Braunwald E, Hauser SL, Jameson JL, et al. Harrison's principles of internal medicine. 18<sup>th</sup> ed. Breast cancer. New York: Mc Graw-Hill;2012. p. 1805-26.
31. Edge SB, Fritz AG, Byrd DR, Greene FL, Compton CC, Trotty A, et al. AJCC cancer staging manual. 7<sup>th</sup> ed. Breast. New York: Springer;2010. p. 347-69.
32. Vanputte C, Regan J, Russo A. Seeley's Essentials Of Anatomy & Physiology. 9<sup>th</sup> ed. Reproductive System. New York: Mc Graw-Hill; 2013. p. 529-59.
33. Buchwalow IB, Bocker W. Immunohistochemistry Basics and Methods. Probes processing in immunohistochemistry. German: Springer; 2010. p. 19-28.
34. Moon IS, Lee HS, Park SD, Seog DH. Immunonucleochemistry: a new method for in situ detection of antigens in the nucleus of cells in culture. Cytotechnology. 2010 Apr; 62(2): 83–93.
35. Abbas AK, Lichtman AH, Pillai S. Cellular and Molecular Immunology. 8<sup>th</sup> ed. Antibodies and antigens. Canada: Elsevier;2015. p.87-106.
36. Kumar LG. Immunohistochemical Staining Methods. 5<sup>th</sup> ed. Boenisch T, editor. Basic Immunochemistry. California: DAKO;2009. p. 11-14.
37. Kraus JA, Dabbs DJ, Beriwal S, Bargava R. Semi-quantitative immunohistochemical assay versus oncotype DX<sup>®</sup> qRT-PCR assay for estrogen and progesterone receptors: an independent quality assurance study. Modern Pathology 2012;25:869–876.
38. Hammond MEH, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S. American Society of Clinical Oncology/College of American Pathologists Guideline Recommendations for Immunohistochemical Testing of Estrogen and Progesterone Receptors in Breast Cancer. Arch Pathol Lab Med. 2010 Jul;134(7):48-72.
39. DAKO [Internet]. ER/PR pharmDx Interpretation Manual.Literature Order No. 28252. Available from: [http://www.dako.com/dist/28252\\_er-pr\\_pharmdx\\_interpretation\\_manual.pdf](http://www.dako.com/dist/28252_er-pr_pharmdx_interpretation_manual.pdf)

40. Wolff AC, Hammond MEH, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Update. *J Clin Oncol*. 2013 Nov 1;31(31):3997-4013.
41. DAKO [Internet]. Herceptest Interpretation Manual Breast Cancer. Literature Order No. 28630. Available from: [http://www.dako.com/dist/28630\\_herceptest\\_interpretation\\_manual-breast\\_ihc\\_row.pdf](http://www.dako.com/dist/28630_herceptest_interpretation_manual-breast_ihc_row.pdf)
42. Ermiah E, Buhmeida A, Abdalla F, Khaled BR, Salem N, Pyrhönen S, et al. Prognostic value of proliferation markers: immunohistochemical ki-67 expression and cytometric s-phase fraction of women with breast cancer in libya. *J Cancer*. 2012;3:421-31.
43. Dowsett M, Nielsen TO, A'Hern R, Bartlett J, Coombes RC, Cuzick J, et al. Assessment of Ki67 in breast cancer: recommendations from the International Ki67 in Breast Cancer working group. *J Natl Cancer Inst*. 2011 Nov 16;103(22):1656-64.
44. Goldhirsch A, Winer EP, Coates AS, Gelber RD, Piccart-Gebhart M, Thürlimann B, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. *Ann Oncol*. 2013 Sep;24(9):2206-23.
45. Engstrøm MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. *Breast Cancer Res Treat*. 2013; 140(3): 463–73.
46. Wiguna NIP, Manuaba IBTW. Karakteristik pemeriksaan imunohistokimia pada pasien kanker payudara di RSUP Sanglah periode 2003-2012. *Jurnal Medika Udayana* 2014 Sep;3(7):1-13.
47. Xue C, Wang X, Peng R, Shi Y, Qin T, Liu D, et al. Distribution, clinicopathologic features and survival of breast cancer subtypes in Southern China. *Cancer Sci*. 2012 Sep;103(9):1679-87.

48. Yanagawa M, Ikemot K, Kawauchi S, Furuya T, Yamamoto S, Oka M, et al. Luminal A and luminal B (HER2 negative) subtypes of breast cancer consist of a mixture of tumors with different genotype. Yanagawa et al. *BMC Research Notes*. 2012;5:376.
49. El Fatemi H, Chahbouni S, Jayi S, Moumna K, Melhouf MA, Bannani A, et al. Luminal B tumors are the most frequent molecular subtype in breast cancer of North African women: an immunohistochemical profile study from Morocco. *Diagn Pathol*. 2012 Dec 7;7:170.
50. Anggo M, Ade W, Syofra E. Profil imunohistokimia pasien kanker payudara di bagian patologi anatomi RSUD Arifin Achmad Pekanbaru periode Januari 2010- Desember 2011. Repository university of Riau [Internet]. 2013 July [cited 2015 may 18]: [about 1p]. Available from: <http://repository.unri.ac.id/xmlui/handle/123456789/4735>
51. Dolle JM, Daling JR, White E, Brinton LA, Doody DR, Porter PL, et al. Risk Factors for Triple-Negative Breast Cancer in Women Under the Age of 45 Years. *Cancer Epidemiol Biomarkers Prev* April 2009 18; 1157.